Epidermal growth factor receptor (EGFR) inhibitors and derived treatments
Epidermal growth factor receptor inhibitors are used to treat advanced lung cancer patients for almost a decade. Current knowledge on their role in the first or subsequent lines of therapy serves as a model for other targeted therapies in development. Several molecular predictors of outcomes were su...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2012-09, Vol.23 Suppl 10, p.x193-x196 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | x196 |
|---|---|
| container_issue | |
| container_start_page | x193 |
| container_title | Annals of oncology |
| container_volume | 23 Suppl 10 |
| creator | Dziadziuszko, R Jassem, J |
| description | Epidermal growth factor receptor inhibitors are used to treat advanced lung cancer patients for almost a decade. Current knowledge on their role in the first or subsequent lines of therapy serves as a model for other targeted therapies in development. Several molecular predictors of outcomes were successfully identified in preclinical and clinical studies. Evaluation of EGFR-activating mutations is currently used to define biologically distinct patient subsets with important consequences for prognosis and therapy. Ongoing translational and clinical research exploring EGFR inhibition in lung cancer focuses on better understanding of biology of EGFR-driven disease, efficacy of novel irreversible EGFR inhibitors and monoclonal antibodies, efficacy of combination strategies, and attempts to move EGFR inhibitors into therapy portfolio for early-stage disease. |
| doi_str_mv | 10.1093/annonc/mds351 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1080613791</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1080613791</sourcerecordid><originalsourceid>FETCH-LOGICAL-c332t-f81b83e480c61d23a7794e9e7b198ecbd05e24111984ce29e6aa0fd4089ed9a13</originalsourceid><addsrcrecordid>eNo9kD1PwzAQhi0EoqUwsqKMZQj1VxJ7RFVbKlVCQjBHjn2hRokTbBfEvydVCtPdvXruHR6Ebgl-IFiyhXKuc3rRmsAycoamJMtlKjAn52iKJWVpkTE-QVchfGCMc0nlJZpQKkUhczJF21VvDfhWNcm7777jPqmVjp1PPGjoj8t8tVm_3CfW7W1lhyAkyplk-LFfYJLoQcUWXAzX6KJWTYCb05yht_XqdfmU7p432-XjLtWM0ZjWglSCARdY58RQpopCcpBQVEQK0JXBGVBOyHBxDVRCrhSuDcdCgpGKsBmaj7297z4PEGLZ2qChaZSD7hBKggXOCSvkEU1HVPsuBA912XvbKv8zQOXRXjnaK0d7A393qj5ULZh_-k8X-wVU02z0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1080613791</pqid></control><display><type>article</type><title>Epidermal growth factor receptor (EGFR) inhibitors and derived treatments</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Dziadziuszko, R ; Jassem, J</creator><creatorcontrib>Dziadziuszko, R ; Jassem, J</creatorcontrib><description>Epidermal growth factor receptor inhibitors are used to treat advanced lung cancer patients for almost a decade. Current knowledge on their role in the first or subsequent lines of therapy serves as a model for other targeted therapies in development. Several molecular predictors of outcomes were successfully identified in preclinical and clinical studies. Evaluation of EGFR-activating mutations is currently used to define biologically distinct patient subsets with important consequences for prognosis and therapy. Ongoing translational and clinical research exploring EGFR inhibition in lung cancer focuses on better understanding of biology of EGFR-driven disease, efficacy of novel irreversible EGFR inhibitors and monoclonal antibodies, efficacy of combination strategies, and attempts to move EGFR inhibitors into therapy portfolio for early-stage disease.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mds351</identifier><identifier>PMID: 22987961</identifier><language>eng</language><publisher>England</publisher><subject>Afatinib ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents - therapeutic use ; Biomarkers, Pharmacological ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Cetuximab ; ErbB Receptors - antagonists & inhibitors ; ErbB Receptors - genetics ; Erlotinib Hydrochloride ; Gefitinib ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Neoplasm Staging ; Prognosis ; Quinazolines - therapeutic use ; Quinolines - therapeutic use ; Translational Medical Research ; Treatment Outcome</subject><ispartof>Annals of oncology, 2012-09, Vol.23 Suppl 10, p.x193-x196</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c332t-f81b83e480c61d23a7794e9e7b198ecbd05e24111984ce29e6aa0fd4089ed9a13</citedby><cites>FETCH-LOGICAL-c332t-f81b83e480c61d23a7794e9e7b198ecbd05e24111984ce29e6aa0fd4089ed9a13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22987961$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dziadziuszko, R</creatorcontrib><creatorcontrib>Jassem, J</creatorcontrib><title>Epidermal growth factor receptor (EGFR) inhibitors and derived treatments</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Epidermal growth factor receptor inhibitors are used to treat advanced lung cancer patients for almost a decade. Current knowledge on their role in the first or subsequent lines of therapy serves as a model for other targeted therapies in development. Several molecular predictors of outcomes were successfully identified in preclinical and clinical studies. Evaluation of EGFR-activating mutations is currently used to define biologically distinct patient subsets with important consequences for prognosis and therapy. Ongoing translational and clinical research exploring EGFR inhibition in lung cancer focuses on better understanding of biology of EGFR-driven disease, efficacy of novel irreversible EGFR inhibitors and monoclonal antibodies, efficacy of combination strategies, and attempts to move EGFR inhibitors into therapy portfolio for early-stage disease.</description><subject>Afatinib</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biomarkers, Pharmacological</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Cetuximab</subject><subject>ErbB Receptors - antagonists & inhibitors</subject><subject>ErbB Receptors - genetics</subject><subject>Erlotinib Hydrochloride</subject><subject>Gefitinib</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Quinazolines - therapeutic use</subject><subject>Quinolines - therapeutic use</subject><subject>Translational Medical Research</subject><subject>Treatment Outcome</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kD1PwzAQhi0EoqUwsqKMZQj1VxJ7RFVbKlVCQjBHjn2hRokTbBfEvydVCtPdvXruHR6Ebgl-IFiyhXKuc3rRmsAycoamJMtlKjAn52iKJWVpkTE-QVchfGCMc0nlJZpQKkUhczJF21VvDfhWNcm7777jPqmVjp1PPGjoj8t8tVm_3CfW7W1lhyAkyplk-LFfYJLoQcUWXAzX6KJWTYCb05yht_XqdfmU7p432-XjLtWM0ZjWglSCARdY58RQpopCcpBQVEQK0JXBGVBOyHBxDVRCrhSuDcdCgpGKsBmaj7297z4PEGLZ2qChaZSD7hBKggXOCSvkEU1HVPsuBA912XvbKv8zQOXRXjnaK0d7A393qj5ULZh_-k8X-wVU02z0</recordid><startdate>201209</startdate><enddate>201209</enddate><creator>Dziadziuszko, R</creator><creator>Jassem, J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201209</creationdate><title>Epidermal growth factor receptor (EGFR) inhibitors and derived treatments</title><author>Dziadziuszko, R ; Jassem, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c332t-f81b83e480c61d23a7794e9e7b198ecbd05e24111984ce29e6aa0fd4089ed9a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Afatinib</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biomarkers, Pharmacological</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Cetuximab</topic><topic>ErbB Receptors - antagonists & inhibitors</topic><topic>ErbB Receptors - genetics</topic><topic>Erlotinib Hydrochloride</topic><topic>Gefitinib</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Quinazolines - therapeutic use</topic><topic>Quinolines - therapeutic use</topic><topic>Translational Medical Research</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dziadziuszko, R</creatorcontrib><creatorcontrib>Jassem, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dziadziuszko, R</au><au>Jassem, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epidermal growth factor receptor (EGFR) inhibitors and derived treatments</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2012-09</date><risdate>2012</risdate><volume>23 Suppl 10</volume><spage>x193</spage><epage>x196</epage><pages>x193-x196</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Epidermal growth factor receptor inhibitors are used to treat advanced lung cancer patients for almost a decade. Current knowledge on their role in the first or subsequent lines of therapy serves as a model for other targeted therapies in development. Several molecular predictors of outcomes were successfully identified in preclinical and clinical studies. Evaluation of EGFR-activating mutations is currently used to define biologically distinct patient subsets with important consequences for prognosis and therapy. Ongoing translational and clinical research exploring EGFR inhibition in lung cancer focuses on better understanding of biology of EGFR-driven disease, efficacy of novel irreversible EGFR inhibitors and monoclonal antibodies, efficacy of combination strategies, and attempts to move EGFR inhibitors into therapy portfolio for early-stage disease.</abstract><cop>England</cop><pmid>22987961</pmid><doi>10.1093/annonc/mds351</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2012-09, Vol.23 Suppl 10, p.x193-x196 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1080613791 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Afatinib Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Agents - therapeutic use Biomarkers, Pharmacological Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Cetuximab ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Erlotinib Hydrochloride Gefitinib Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Neoplasm Staging Prognosis Quinazolines - therapeutic use Quinolines - therapeutic use Translational Medical Research Treatment Outcome |
| title | Epidermal growth factor receptor (EGFR) inhibitors and derived treatments |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T04%3A46%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epidermal%20growth%20factor%20receptor%20(EGFR)%20inhibitors%20and%20derived%20treatments&rft.jtitle=Annals%20of%20oncology&rft.au=Dziadziuszko,%20R&rft.date=2012-09&rft.volume=23%20Suppl%2010&rft.spage=x193&rft.epage=x196&rft.pages=x193-x196&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mds351&rft_dat=%3Cproquest_cross%3E1080613791%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1080613791&rft_id=info:pmid/22987961&rfr_iscdi=true |